Call our 24 hours, seven days a week helpline at 800.272.3900
Let us connect you to professionals and support options near you. Please select an option below:
Use Current LocationUse Map Selector
Your holiday gift today will provide much-needed care and support to the millions of families facing Alzheimer's, while advancing critical research to help end this disease.
Production aims to reduce Alzheimer’s disease stigma, educate and entertain underserved communities
Public health veteran and Association president signals continued focus on scientific progress and access for treatments for all who will benefit
Association Renews Urgent Call for CMS to Cover FDA-Approved Alzheimer’s Treatments
The FDA determined that additional data is required to reach a decision on accelerated approval of donanemab.
Leading researchers and community leaders convene in Tempe, Ariz. on February 8-9
As a patient advocacy group and evidence-based organization, the Alzheimer’s Association stands behind people living with Alzheimer’s.
Lisa Barnes, Ph.D. is the new deputy editor of Alzheimer's & Dementia, the Alzheimer's Association's journal.
The Alzheimer’s Association and AIM are proud to support the reintroduction of the NAPA Reauthorization Act and the Alzheimer’s Accountability & Investment Act.
An expert work group has developed an improved definition of clinical meaningfulness in Alzheimer's.
The Alzheimer’s Association and MATTER selected the winner and runners up in the competition to develop new tools for early assessment of Alzheimer's.
Part the Cloud, in partnership with the Alzheimer’s Association, was announced today as Best Health Fundraising Event in the 2nd Annual Anthem Awards.
The Alzheimer’s Association appreciates the generosity of the Erb Family Foundation and its ongoing commitment to advance Alzheimer’s and dementia research
The Centers for Medicare & Medicaid Services has refused to change its coverage of FDA-approved Alzheimer's treatments, despite significant new evidence.
Comprehensive Care for Alzheimer’s Act
Leaders of the U.S. POINTER Study announced a historic milestone: recruiting for the clinical trial has been successfully completed.
The Alzheimer’s Association is disappointed by the topline results from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) Study of solanezumab.
We appreciate the agency’s thoughtful approach to making this decision.
The 2023 Facts and Figures report examines patients' and doctors' reluctance to address memory concerns, which hinders diagnosis and access to new treatments.
Comprehensive Care for Alzheimer’s Act introduced in U.S. House
The senators were each named the 2023 AIM Humanitarian of the Year at the National Alzheimer’s Dinner, during the AIM Advocacy Forum.
Comedian Discusses the Power of Laughter as a Caregiver
Ultraprocessed Foods May Speed Cognitive Decline
Animal Therapy Helps People Navigate Dementia
Museum Programs Inspire Those Facing Alzheimer’s
Actress' Struggle with Alzheimer’s Put the Disease in the Spotlight
Studies Show Discrimination May Cause Cognitive Decline
Alzheimer’s Association advocates flood Senate budget hearings to push HHS secretary to cover Alzheimer’s treatments.
New PSAs from the Ad Council, Alzheimer’s Association and NASCAR encourage families to talk about seeing a doctor together at the first signs of dementia.
The Alzheimer’s Association and bipartisan advocates urged the HHS secretary to cover FDA-approved Alzheimer’s treatments in this week's House budget hearings.
The Alzheimer’s Association commits $10.85 million to a venture capital fund that invests in companies developing promising treatments for Alzheimer’s.
The Alzheimer’s Association recognized six pioneers in neuroscience research and mentorship at the third AAIC® Neuroscience Next conference.
More than 200 attendees gathered to hear from leading Alzheimer’s experts about how Part the Cloud propels progress in dementia research.
Scientists, clinicians and health professionals will discuss the latest Alzheimer’s and dementia research in Latin America at the AAIC Satellite Symposium.
Bipartisan members sharply questioned the Centers for Medicare & Medicaid Services about why FDA-approved Alzheimer’s drugs aren’t "reasonable and necessary."
Despite mounting bipartisan political pressure, CMS continues to deny Medicare beneficiaries living with early Alzheimer's access to FDA-approved treatments.
The Alzheimer's Association welcomes the positive data on the Phase 3 clinical trial of donanemab for treatment of early symptomatic Alzheimer's disease.
The Alzheimer's Association has enhanced ALZNavigator and ALZConnected to support individuals affected by Alzheimer’s and dementia and their caregivers.
Tony Gonzales testified before the House Ways and Means Health Subcommittee on what access to treatments would mean for the Alzheimer’s community.
The Alzheimer’s Association welcomes the approval of brexpiprazole (Rexulti®), the first FDA-approved treatment to address dementia-related agitation.
The Alzheimer's Association and members of the Early Stage Advisory Group urged the FDA to recommend traditional approval of Leqembi.
The Alzheimer’s Association expresses our deepest appreciation to former first lady Rosalynn Carter and her family for sharing her diagnosis of dementia.
During Alzheimer’s & Brain Awareness Month, the Association is ramping up its efforts to make FDA-approved treatments for early-stage Alzheimer's accessible.
CMS (Medicare) announced its approach to coverage of Alzheimer's treatments with traditional FDA-approval, requiring that clinicians join a registry for access.
Guyton’s song, “How You Love Someone” will raise awareness and encourage more conversations about Alzheimer's and other dementia.
Together, the Alzheimer’s Association and The Links, Incorporated, will provide Alzheimer’s disease information and resources to Black American communities.
FDA Advisory Committee unanimously endorsed the efficacy and clinical benefit of lecanemab as part of the traditional approval process for this treatment.
Leaders in health equity have issued an urgent call to address the underrepresentation of U.S. Latinos in Alzheimer's and dementia clinical trials.
The Senate passed the bipartisan NAPA Reauthorization Act and the Alzheimer’s Accountability & Investment Act to accelerate the fight against all dementia.
The new HBI Road Map provides public health officials with strategies to promote brain health and improve the quality of life for people impacted by dementia.
New report highlights the Association’s wide-ranging work in engaging diverse communities in reducing health disparities and achieving health equity.
NASCAR driver Ryan Blaney presented a $50,000 check to the Alzheimer’s Association to help advance Alzheimer's research support families impacted by dementia.
The Alzheimer’s Association celebrates today’s FDA action to grant traditional approval of Leqembi (lecanemab) for the treatment of early Alzheimer’s disease.
UPDATED: The Alzheimer’s Association celebrates the FDA action to grant traditional approval to Leqembi (lecanemab) for the treatment of early Alzheimer’s.
The Association will work with payers & health systems to deliver broad access, calling on CMS to open reconsideration of its National Coverage Determination.
This specialty certification recognizes assisted living communities that implement best practices for residents living with Alzheimer’s disease or dementia.
Seven awards were presented to researchers at AAIC 2023 to honor their expertise, achievements & contributions to the field of Alzheimer’s & dementia science.
"Through both her passionate storytelling & leadership of The Judy Fund, [Gelfand Stearns] is a relentless champion in the fight to end Alzheimer’s disease."
AAIC 2023 announces two new CRISPR-based strategies that offer hope for next-generation Alzheimer’s treatments.
A draft proposal for new Alzheimer’s disease diagnostic criteria was presented to attendees of AAIC 2023. They are a revision of the 2018 research framework.
The east & southeastern U.S. have the highest prevalence of Alzheimer’s, according to a first-ever study of the disease by county, presented at AAIC 2023.
Los resultados pueden ayudar a orientar la asignación de recursos a los programas de salud pública para el Alzheimer en esas regiones.
The results showed that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease.
In a subgroup of older adults with hearing loss who were at higher risk of cognitive decline, using hearing aids for three years cut cognitive decline in half.
The Alzheimer’s Association commends CMS for taking action to expand coverage of brain amyloid PET imaging for the diagnosis of Alzheimer’s disease.
Older adults who start on opioids after a dementia diagnosis face heightened risk of death, according to a study reported at AAIC 2023.
Experiencing less frequent bowel movements is associated with cognitive decline, according to new research reported today at AAIC 2023.
El estreñimiento crónico, un movimiento intestinal cada tres días o más, podría indicar un empeoramiento de la cognición.
A blood test was more than 80% accurate than doctors in identifying Alzheimer’s-related changes, a new study at AAIC reports.
Alzheimer's advocate Sue Wronsky testified before Congress, supporting unrestricted CMS coverage for Alzheimer’s treatments that are approved by the FDA.
A new study reported at AAIC 2023 found better memory cognition in older adults who volunteered. Volunteering may help protect the brain against dementia.
Un nuevo estudio sobre adultos mayores descubrió que quienes trabajaban como voluntarios tienen una mejor memoria y función ejecutiva.
AAIC 2023 featured groundbreaking research & guidance on an Alzheimer's blood test, gut health, hearing aid intervention, opioids, gene editing and more.
Nuevas investigaciones reportadas en el AAIC cubrieron la amplitud de la investigación de la enfermedad de Alzheimer y la demencia.
The Alzheimer’s Association is deeply saddened by the death of legendary singer Tony Bennett, an incredible advocate who publicly shared his story.
The Alzheimer's Association enthusiastically welcomes the announcement of a new CMS initiative to improve the way dementia care is delivered.
The roundtable will convene experts across the healthcare industry to establish consistent processes and protocols for dementia care navigation.
New PSAs from Ad Council, Alzheimer’s Association & Lopez Negrete Communications show early warning signs of Alzheimer’s that can be mistaken for normal aging.
As the new vice chair of the World Dementia Council, Pike will advance the organization’s global efforts to improve the lives of people affected by dementia.
The Alzheimer’s Association welcomes Eisai as a national sponsor of Walk to End Alzheimer’s, the largest fundraiser for Alzheimer’s care, support & research.
The Alzheimer's Association will award up to $5 million in funding to platforms outside the U.S. through the Global Real-World Data Platforms Program (ALZ-RWD).
The Alzheimer’s Association brings together state officials for its second annual State Dementia Services Coordinator (DSC) Summit.
A valuable Alzheimer’s disease diagnostic tool, PET scans, will now be more accessible across the country thanks to today's Medicare & Medicaid policy change.
During National Family Caregivers Month in November, the Alzheimer’s Association highlights the unique challenges facing Alzheimer’s and dementia caregivers.
A total of 26 awards have been granted to projects aimed at bridging the gaps in dementia diagnosis, treatment and care among underserved populations worldwide.
This unparalleled commitment stands as the largest single-year investment since the organization’s founding in 1980.
The Alzheimer’s Association is saddened by the death of former First Lady Rosalynn Carter.
Donate Now
Take the Brain Tour
Learn More